Using personal examples, Dr Gavin Corcoran, Chief Development Officer of Formation Bio discusses where AI can positively impact clinical development and how CMOs can think about investing in AI solutions. Formation Bio acquires or in-licenses drug assets from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging their proprietary tech and AI capabilities, ultimately helping to bring new medicines to patients.
Featured Editorial
